RSV PREVENTION IN OLDER ADULTS: A MINI REVIEW OF APPROVED VACCINES

Martyna Sternik; Agnieszka Dobrowolska; Hanna Ćwirko; Zuzanna Drewniak; Marta Rząsa; Karolina Rycman; Adam Skrobarczyk; Kamil Wendrychowicz; Filip Wróbel

doi:10.31435/ijitss.4(48).2025.4529

Authors

Martyna Sternik 4th Military Clinical Hospital with Polyclinic in Wrocław, Wrocław, Poland https://orcid.org/0009-0003-2235-7932
Agnieszka Dobrowolska Provincial Hospital in Zgierz them. M. Skłodowska-Curie, Zgierz, Poland https://orcid.org/0009-0000-5645-7518
Hanna Ćwirko University Clinical Hospital of Jan Mikulicz-Radecki in Wrocław, Wrocław, Poland https://orcid.org/0009-0005-4947-5343
Zuzanna Drewniak Praski Hospital in Warsaw, Warsaw, Poland https://orcid.org/0009-0006-0426-4312
Marta Rząsa Provincial Hospital in Zgierz them. M. Skłodowska-Curie, Zgierz, Poland https://orcid.org/0009-0000-6817-6940
Karolina Rycman Clinical Hospital of the Poznań University of Medical Sciences, Poznań, Poland https://orcid.org/0009-0006-8144-6339
Adam Skrobarczyk 4th Military Clinical Hospital with Polyclinic in Wrocław, Wrocław, Poland https://orcid.org/0009-0006-6391-2666
Kamil Wendrychowicz Central Teaching Hospital of the Medical University of Lodz, Łódź, Poland https://orcid.org/0009-0005-5452-5384
Filip Wróbel Norbert Barlicki Memorial Teaching Hospital No. 1 of the Medical University of Lodz, Łódź, Poland https://orcid.org/0009-0000-7572-9451

DOI:

https://doi.org/10.31435/ijitss.4(48).2025.4529

Keywords:

Respiratory Syncytial Virus, Respiratory Syncytial Virus Infections, Adult, Aged, Vaccination, Vaccine Efficacy

Abstract

Respiratory syncytial virus (RSV) is a major cause of severe respiratory illness, imposing a substantial global health burden on older adults. For decades, the development of a safe and effective vaccine for adults was hindered by challenges, including the experience with an early formalin-inactivated vaccine that caused enhanced disease. A recent advancement in vaccinology, based on structure-guided design of immunogens that stabilize the viral fusion (F) glycoprotein in its prefusion form, has enabled the development and approval of three vaccines for older adults - two protein subunit vaccines: Arexvy, Abrysvo and one mRNA based mRESVIA. This review, based on studies identified through PubMed and Google Scholar using various keywords combinations, introduces the recently approved RSV vaccines, their composition, clinical efficacy, duration of protection, and uptake. Studies have shown that a single dose of these vaccines provides up to 82.6% efficacy against RSV-associated lower respiratory tract disease and 71.7% efficacy against RSV-associated acute respiratory infection within a single RSV season, highlighting their potential to reduce the burden of RSV in this population. As RSV infections continue to pose a significant risk and these vaccines have only been approved within the past two years, it is crucial to raise awareness about preventive measures.

References

Melgar, M. (2023). Use of respiratory syncytial virus vaccines in older adults: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023. MMWR. Morbidity and Mortality Weekly Report, 72, Article mm7229a4. https://doi.org/10.15585/mmwr.mm7229a4

Nam, H. H., & Ison, M. G. (2019). Respiratory syncytial virus infection in adults. BMJ, 366, l5021. https://doi.org/10.1136/bmj.l5021

Papi, A., Ison, M. G., Langley, J. M., Lee, D. G., Leroux-Roels, I., Martinón-Torres, F., & Hulstrøm, V. (2023). Respiratory syncytial virus prefusion F protein vaccine in older adults. New England Journal of Medicine, 388(7), 595–608. https://doi.org/10.1056/NEJMoa2209604

Bigoni, T., Alfano, F., Aloe, F., Baraldi, F., Caggiano, F. P., de Tarczal, O. D. A., & Papi, A. (2025). Respiratory syncytial virus prevention in the adult population: State of the art. Seminars in Respiratory and Critical Care Medicine, 46(1), 41–52. https://doi.org/10.1055/a-2586-3974

Graham, B. S. (2011). Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunological Reviews, 239(1), 149–166. https://doi.org/10.1111/j.1600-065X.2010.00972.x

Guvenel, A. K., Chiu, C., & Openshaw, P. J. (2014). Current concepts and progress in RSV vaccine development. Expert Review of Vaccines, 13(3), 333–344. https://doi.org/10.1586/14760584.2014.878653

Che, Y., Gribenko, A. V., Song, X., Handke, L. D., Efferen, K. S., Tompkins, K., & Swanson, K. A. (2023). Rational design of a highly immunogenic prefusion-stabilized F glycoprotein antigen for a respiratory syncytial virus vaccine. Science Translational Medicine, 15(693), eade6422. https://doi.org/10.1126/scitranslmed.ade6422

Anfaal, Z., Khan, Z. A., & Aslam, M. A. (2025). FDA approves mRESVIA: Embracing the new era of RSV prevention with advanced mRNA technology. Annals of Pharmacotherapy, 59(7). https://doi.org/10.1177/10600280241301432

Htar, M. T. T., Yerramalla, M. S., Moïsi, J. C., & Swerdlow, D. L. (2020). The burden of respiratory syncytial virus in adults: A systematic review and meta-analysis. Epidemiology & Infection, 148, e48. https://doi.org/10.1017/S0950268820000400

Drews, S. J., Branche, A. R., Falsey, A. R., & Lee, N. (2019). What is the role of rapid molecular testing for seniors and other at-risk adults with respiratory syncytial virus infections? Journal of Clinical Virology, 117, 27–32. https://doi.org/10.1016/j.jcv.2019.05.010

Allen, K. E., Chommanard, C., Haynes, A. K., Erdman, D. D., Gerber, S. I., & Kim, L. (2018). Respiratory syncytial virus testing capabilities and practices among National Respiratory and Enteric Virus Surveillance System laboratories, United States, 2016. Journal of Clinical Virology, 107, 48–51. https://doi.org/10.1016/j.jcv.2018.08.009

Sáez-López, E., Pechirra, P., Costa, I., Cristóvão, P., Conde, P., Machado, A., & Guiomar, R. (2019). Performance of surveillance case definitions for respiratory syncytial virus infections through the sentinel influenza surveillance system, Portugal, 2010 to 2018. Eurosurveillance, 24(45), 1900140. https://doi.org/10.2807/1560-7917.ES.2019.24.45.1900140

Kestler, M., Muñoz, P., Mateos, M., Adrados, D., & Bouza, E. (2018). Respiratory syncytial virus burden among adults during flu season: An underestimated pathology. Journal of Hospital Infection, 100(4), 463–468. https://doi.org/10.1016/j.jhin.2018.03.034

Schubert, L., Steininger, J., Lötsch, F., Herdina, A. N., Redlberger-Fritz, M., Tobudic, S., & Steininger, C. (2021). Surveillance of respiratory syncytial virus infections in adults, Austria, 2017 to 2019. Scientific Reports, 11(1), 8939. https://doi.org/10.1038/s41598-021-88537-5

Nguyen-Van-Tam, J. S., O'Leary, M., Martin, E. T., Heijnen, E., Callendret, B., Fleischhackl, R., & Weber, K. (2022). Burden of respiratory syncytial virus infection in older and high-risk adults: A systematic review and meta-analysis of the evidence from developed countries. European Respiratory Review, 31(166). https://doi.org/10.1183/16000617.0105-2022

Huijts, S. M., Coenjaerts, F. E. J., Bolkenbaas, M., Van Werkhoven, C. H., Grobbee, D. E., Bonten, M. J. M., & CAPiTA Study Team. (2018). The impact of 13-valent pneumococcal conjugate vaccination on virus-associated community-acquired pneumonia in elderly: Exploratory analysis of the CAPiTA trial. Clinical Microbiology and Infection, 24(7), 764–770. https://doi.org/10.1016/j.cmi.2017.10.006

Savic, M., Penders, Y., Shi, T., Branche, A., & Pirçon, J. Y. (2023). Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: A systematic literature review and meta-analysis. Influenza and Other Respiratory Viruses, 17(1), e13031. https://doi.org/10.1111/irv.13031

Shi, T., Denouel, A., Tietjen, A. K., Campbell, I., Moran, E., Li, X., & Nair, H. (2020). Global disease burden estimates of respiratory syncytial virus–associated acute respiratory infection in older adults in 2015: A systematic review and meta-analysis. Journal of Infectious Diseases, 222(Suppl 7), S577–S583. https://doi.org/10.1093/infdis/jiz059

Anastassopoulou, C., Medić, S., Ferous, S., Boufidou, F., & Tsakris, A. (2025). Development, current status, and remaining challenges for respiratory syncytial virus vaccines. Vaccines, 13(2), 97. https://doi.org/10.3390/vaccines13020097

Mboup, E. B., Hamelin, M. È., Dubois, J., Rosa-Calatrava, M., & Boivin, G. (2025). Vaccine development for human pneumoviruses. Vaccines, 13(6), 569. https://doi.org/10.3390/vaccines13060569

Britton, A., Roper, L. E., Kotton, C. N., Hutton, D. W., Fleming-Dutra, K. E., Godfrey, M., & Melgar, M. (2024). Use of respiratory syncytial virus vaccines in adults aged ≥60 years: Updated recommendations of the Advisory Committee on Immunization Practices—United States, 2024. MMWR. Morbidity and Mortality Weekly Report, 73(32), 696–702. https://doi.org/10.15585/mmwr.mm7332e1

U.S. Food and Drug Administration. (2023). Approval letter: Arexvy. https://www.fda.gov/media/167806/download

European Medicines Agency. (2023). European public assessment report (EPAR): Arexvy. https://www.ema.europa.eu/en/medicines/human/EPAR/arexvy

GlaxoSmithKline. (2024). AREXVY package insert. https://www.fda.gov/media/167805/download

Parums, D. V. (2025). Surveillance of seasonal respiratory syncytial virus (RSV) infection in children and vulnerable adults drives vaccine development and new immunization programs. Medical Science Monitor, 31, e949558. https://doi.org/10.12659/MSM.949558

U.S. Food and Drug Administration. (2023). Summary basis for regulatory action: AREXVY. https://www.fda.gov/media/168519/download

Mboup, E. B., Hamelin, M. È., Dubois, J., Rosa-Calatrava, M., & Boivin, G. (2025). Vaccine development for human pneumoviruses. Vaccines, 13(6), 569. https://doi.org/10.3390/vaccines13060569

Leroux-Roels, I., Davis, M. G., Steenackers, K., Essink, B., Vandermeulen, C., Fogarty, C., & Hulstrøm, V. (2023). Safety and immunogenicity of a respiratory syncytial virus prefusion F (RSVPreF3) candidate vaccine in older adults: Phase 1/2 randomized clinical trial. Journal of Infectious Diseases, 227(6), 761–772. https://doi.org/10.1093/infdis/jiac327

Schwarz, T. F., Hwang, S. J., Ylisastigui, P., Liu, C. S., Takazawa, K., Yono, M., & Hulstrøm, V. (2024). Immunogenicity and safety following 1 dose of AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine in older adults: A phase 3 trial. Journal of Infectious Diseases, 230(1), e102–e110. https://doi.org/10.1093/infdis/jiad546

Ison, M. G., Papi, A., Athan, E., Feldman, R. G., Langley, J. M., Lee, D. G., & AReSVi-006 Study Group. (2024). Efficacy and safety of respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons. Clinical Infectious Diseases, 78(6), 1732–1744. https://doi.org/10.1093/cid/ciae010

Pfizer Inc. (2024). ABRYSVO package insert. https://www.fda.gov/media/168889/download

Baber, J., Arya, M., Moodley, Y., Jaques, A., Jiang, Q., Swanson, K. A., & Schmoele-Thoma, B. (2022). A phase 1/2 study of a respiratory syncytial virus prefusion F vaccine with and without adjuvant in healthy older adults. Journal of Infectious Diseases, 226(12), 2054–2063. https://doi.org/10.1093/infdis/jiac189

Walsh, E. E., Falsey, A. R., Scott, D. A., Gurtman, A., Zareba, A. M., Jansen, K. U., & Schmoele-Thoma, B. (2022). A randomized phase 1/2 study of a respiratory syncytial virus prefusion F vaccine. Journal of Infectious Diseases, 225(8), 1357–1366. https://doi.org/10.1093/infdis/jiab612

Walsh, E. E., Pérez Marc, G., Zareba, A. M., Falsey, A. R., Jiang, Q., Patton, M., & RENOIR Clinical Trial Group. (2023). Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. New England Journal of Medicine, 388(16), 1465–1477. https://doi.org/10.1056/NEJMoa2213836

Moderna, Inc. (2024). Moderna receives U.S. FDA approval for RSV vaccine mRESVIA. https://s29.q4cdn.com/435878511/files/doc_news/Moderna-Receives-U.S.-FDA-Approval-for-RSV-Vaccine-mRESVIAR-2024.pdf

Wilson, E., Goswami, J., Baqui, A. H., Doreski, P. A., Perez-Marc, G., Zaman, K., & ConquerRSV Study Group. (2023). Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults. New England Journal of Medicine, 389(24), 2233–2244. https://doi.org/10.1056/NEJMoa2307079

Surie, D., Self, W. H., Yuengling, K. A., Lauring, A. S., Zhu, Y., Safdar, B., & Mariscal, D. (2025). RSV vaccine effectiveness against hospitalization among U.S. adults aged 60 years or older during two seasons. JAMA, 334(16), 1442–1451. https://doi.org/10.1001/jama.2025.15896

Lassen, M. C. H., Johansen, N. D., Christensen, S. H., Aliabadi, N., Skaarup, K. G., Modin, D., & Biering-Sørensen, T. (2025). RSV prefusion F vaccine for prevention of hospitalization in older adults. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2509810

Fry, S. E., Terebuh, P., Kaelber, D. C., Xu, R., & Davis, P. B. (2025). Effectiveness and safety of respiratory syncytial virus vaccine for U.S. adults aged 60 years or older. JAMA Network Open, 8(5), e258322. https://doi.org/10.1001/jamanetworkopen.2025.8322

Lee, B., Trusinska, D., Ferdous, S., Pei, R., Kwok, H. H., Schwarze, J., & Shi, T. (2025). Real-world effectiveness and safety of nirsevimab, RSV maternal vaccine and RSV vaccines for older adults: A living systematic review and meta-analysis. Thorax, 80(11), 838–848. https://doi.org/10.1136/thorax-2025-223376

La, E. M., McGuiness, C. B., Singer, D., Yasuda, M., & Chen, C. C. (2025). RSV vaccination uptake among U.S. adults aged ≥60 years who are at increased risk of severe RSV disease (August 2023–February 2024). Open Forum Infectious Diseases, 12(Suppl 1), ofae631.243. https://doi.org/10.1093/ofid/ofae631.243

Geng, X., & Wang, W. (2024). Respiratory syncytial virus vaccination among U.S. adults aged ≥60 years. Frontiers in Immunology, 15, 1427550. https://doi.org/10.3389/fimmu.2024.1427550

La, E. M., McGuiness, C. B., Singer, D., Yasuda, M., & Chen, C. C. (2025). RSV vaccination uptake among adults aged 60 years and older in the United States during the 2023–2025 vaccination seasons. Human Vaccines & Immunotherapeutics, 21(1), 2535755. https://doi.org/10.1080/21645515.2025.2535755

Shaw, C. A., Essink, B., Harper, C., Mithani, R., Kapoor, A., Dhar, R., & Goswami, J. (2024). Safety and immunogenicity of an mRNA-based RSV vaccine including a 12-month booster in a phase 1 clinical trial in healthy older adults. Journal of Infectious Diseases, 230(3), e647–e656. https://doi.org/10.1093/infdis/jiae081

Comeaux, C. A., Falsey, A. R., Williams, K., Bart, S., Ervin, J. E., Bastian, A. R., & Heijnen, E. (2022). Long-term immunogenicity of Ad26.RSV.preF/RSV preF protein vaccine against RSV in a phase 2b study by age and risk level. Open Forum Infectious Diseases, 9(Suppl 2), ofac492-152. https://doi.org/10.1093/ofid/ofac492.152

Falsey, A. R., Singh, H. K., & Walsh, E. E. (2006). Serum antibody decay in adults following natural respiratory syncytial virus infection. Journal of Medical Virology, 78(11), 1493–1497. https://doi.org/10.1002/jmv.20724

Killikelly, A., Siu, W., Abrams, E. M., & Brousseau, N. (2025). Summary of the National Advisory Committee on Immunization (NACI) statement on the prevention of respiratory syncytial virus (RSV) in older adults. Canada Communicable Disease Report, 51(8), 292. https://doi.org/10.14745/ccdr.v51i08a01

Tong, X., Blanc, R., Cizmeci, D., Malca, H., Kang, J., Comeaux, C., & McNamara, R. (2025). Adenovectored RSV prefusion glycoprotein plus soluble glycoprotein combination immunization establishes persistent opsonophagocytic antibody response through IgG3. Frontiers in Immunology, 16, 1609779. https://doi.org/10.3389/fimmu.2025.1609779